The following content is Conservatives aim to reduce medical costs.
Big Pharma is collaborating with left-wing politicians to force even more government intervention into the medical field (a win for the socialist left) and to give Big Pharma even greater pricing power to set even more uncontrollable prices and higher profits. Pushing ahead with plans to give the company a boost (a boon for price gougers). They are leveraging the power of the free market to leverage pharmacy benefit managers (PBMs) to provide savings to American businesses and patients. Their maneuver will bail out Big Pharma at the expense of hardworking taxpayers, patients, and families, and will intensify the left's move toward a socialist takeover of health care.
Fortunately, there are stalwart conservatives in Congress who are willing to stand up to the left's plan to promote universal health care and stand by taxpayers, corporations, and the American people. Lawmakers such as Rep. Marjorie Taylor Greene (R-Ga.) continue to stand their ground on this issue, rather than taking the bait from Big Pharma like Democrats. saying“We paid big drug companies enough money to pay for their coronavirus vaccines.''Republicans are particularly concerned about spending cuts aimed at weaponizing the Justice Department against President Trump and about Joe Biden's corruption.'' We should focus on starting an impeachment inquiry. We don't have time to push Big Pharma and Dr. Fauci's priorities.”
Recent washington examiner This article reveals how passing legislation targeting pharmacy benefit companies could actually hurt Republicans in the 2024 election cycle.Republican Senate campaign staff warned“Not a single Republican voter is asking the House to pass a PBM bill. This is being driven by pharmaceutical lobbyists, is bad politics and policy, and will hurt us next fall.” ”
The proposals in question not only have serious political implications for conservative policymakers, but also come with dire costs. One policy aimed at prohibiting market-based incentives for PBMs when negotiating with drug companies to secure rebates would reduce federal spending in the Medicare Part D program by $3 billion to $10 billion annually. would increase to dollars. according to Dr. Casey Mulligan, Professor of Economics, University of Chicago
Similar “unlinking” measures have raised concerns among experts, policy makers and community leaders.
Joe Grogan, who served as a domestic policy adviser under former President Trump, slammed “Unlink” policy:
Unfortunately, Congress's eagerness to destroy this contracting arrangement punishes patients and taxpayers far more than it punishes PBMs. In a post-delinking world, PBMs would be paid the same amount for each dispensing of the same type of drug, or a single flat fee for all services, reducing their incentive to negotiate deep discounts. Worse, the employer's only recourse is to address her underperforming PBM without performance-based pricing and switch her PBM when the contract expires.
Additionally, unlinking costs patients money.Reducing the size of negotiated rebates due to incentive elimination means plan premiums will increase by the same amount $10 billion annually For the elderly, patients will have less insurance, limited access to other services, and health spillovers that will increase spending. 600 million dollars.
It is not just policy makers and policy experts who are expressing deep concern about the bill targeting pharmacy benefits, but also community leaders, including small business owners, who believe the leftists and Big Pharma are targeting the agenda. I can see right through it.
Alabama Probate Judge Ryan Robertson warned:
Rather than making things easier for patients and employers, some lawmakers, including Medicare for All supporters Bernie Sanders and Alexandria Ocasio-Cortez, have argued that instead of making things easier for patients and employers, they want to limit options and raise the cost of prescription drugs. Pushing forward with policies that undermine the flexibility that employers rely on. They aim to do this with new government powers that would allow the government to decide what happens in the prescription drug market.
Business owner and former Mississippi state senator Merle Flowers prompted Lawmakers oppose new government order:
The best way to effectively reduce prescription drug spending, or the cost thereof, is to increase competition and strengthen free market forces. Allowing the government to limit, ban, or eliminate the tools that pharmacy benefit companies use to put downward pressure on the cost of prescription drugs will harm not only patients, families, and taxpayers, but our free society as a whole. Now, more than ever, conservative members of Congress must prevent the left from getting their way and turn our country into a government-controlled socialist society. There needs to be a renewed focus on pharmacy benefit companies, starting with rejecting policies that target pharmacy benefit companies.
The policy in question would actually cause huge damage to big pharmaceutical companies. $32 billion Pharmaceutical profits would increase every year if Congress “unlinked” Medicare Part D and PBM compensation in the commercial insurance market. This huge financial windfall for big drug companies explains why they are urging lawmakers to push for such policies. On the other hand, the prospect of significantly expanding the government's role in the health care system to undermine free market principles explains why Democrats are so eager to advance drug companies' priorities. . Republicans are the only line of defense against these false proposals masquerading as solutions to better serve Americans.
For more information, see Conservative for Low Health Care Costs.
